Novan, Inc. NOVN
We take great care to ensure that the data presented and summarized in this overview for Novan, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NOVN
Top Purchases
Top Sells
About NOVN
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Insider Transactions at NOVN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2023
|
Machelle Sanders Director |
SELL
Open market or private sale
|
Direct |
11,553
-31.39%
|
$0
$0.41 P/Share
|
|
Jun 07
2023
|
Steven D Skolsky Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,101
+50.0%
|
-
|
|
Jun 07
2023
|
Robert J Keegan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,101
+45.99%
|
-
|
|
Jun 07
2023
|
James L Bierman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,101
+47.38%
|
-
|
|
Jun 07
2023
|
Machelle Sanders Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,101
+49.52%
|
-
|
|
Jun 07
2023
|
W Kent Geer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,101
+48.93%
|
-
|
|
Jun 07
2023
|
John M. Gay Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,669
-30.62%
|
-
|
|
Jun 07
2023
|
John M. Gay Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+49.06%
|
-
|
|
Apr 07
2022
|
James L Bierman Director |
BUY
Open market or private purchase
|
Direct |
1,000
+20.0%
|
$3,000
$3.45 P/Share
|
|
Mar 28
2022
|
James L Bierman Director |
BUY
Open market or private purchase
|
Direct |
1,000
+25.0%
|
$3,000
$3.45 P/Share
|
|
Mar 25
2022
|
James L Bierman Director |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$6,000
$3.54 P/Share
|
|
Mar 18
2022
|
John M. Gay Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+28.57%
|
$3,000
$3.5 P/Share
|
|
Mar 18
2022
|
John W Palmour Director |
BUY
Open market or private purchase
|
Direct |
10,000
+12.6%
|
$30,000
$3.63 P/Share
|
|
Mar 17
2022
|
John W Palmour Director |
BUY
Open market or private purchase
|
Direct |
5,000
+7.77%
|
$15,000
$3.34 P/Share
|
|
Mar 16
2022
|
John W Palmour Director |
BUY
Open market or private purchase
|
Direct |
5,000
+8.42%
|
$15,000
$3.34 P/Share
|
|
Mar 26
2021
|
Paula B Stafford President and CEO |
BUY
Open market or private purchase
|
Direct |
70,000
+31.72%
|
$70,000
$1.43 P/Share
|